Substitution treatment or active intravenous drug use should not be contraindications forantiviral treatment in drug userswith chronic hepatitis C

Liver International

Volumn 30, Issue 10, 2010, Pages 1454-1460

  Manolakopoulos, Spilios ^a   Deutsch, Melanie J ^a   Anagnostou, Olga ^b   Karatapanis, Stelios ^c   Tiniakou, Elli ^a   Papatheodoridis, George V ^a   Georgiou, Ekaterini ^b   Manesis, Emmanuel ^a   Tzourmakliotis, Dimitris ^b   Archimandritis, Athanasios J ^d  

^a HIPPOKRATION HOSPITAL   (Greece)

^b KAT HOSPITAL   (Greece)

^c General Hospital of Rhodos   (Greece)

^d NONE

Author keywords

Drug users; Hepatitis C; Treatment

Indexed keywords

ALPHA INTERFERON; METHADONE; PEGINTERFERON ALPHA; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; DEPRESSION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PYELONEPHRITIS; SKIN INFECTION; SOFT TISSUE INFECTION; SUBSTITUTION THERAPY; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; DRUG USERS; FEMALE; GENOTYPE; GREECE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK ASSESSMENT; RISK FACTORS; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 79951601238     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02341.x     Document Type: Article

References (24)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29(Suppl. 1): 74-81.
2. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infection in the United States. J Viral Hepat 2007; 14: 107-15.
3. Cook PA, McVeigh J, Sjed Q, Mutton K, Bellis MA. Predictors of hepatitis B and C infection in injecting drug users both in and out of drug treatment. Addiction 2001; 96: 1787-97.
4. Miller CL, Johnston C, Spittal PM, et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002; 36: 737-42.
5. Robaeys G, Van Vlierberghe H, Matheï C, et al. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol 2006; 18: 159-66.
6. Belfiori B, Ciliegi P, Chiodera A, et al. Peginterferon plus ribavirin for chronic hepatitis C in opiate addicts on methadone/buprenorphine maintenance therapy. Dig Liver Dis 2009; 41: 303-7.
7. Guadagnino V, Trotta MP, Montesano F, et al. Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes. Addiction 2007; 102: 423-31.
8. Bonkovsky HL, Tice AD, Yapp RG, et al. Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. Am J Gastroenterol 2008; 103: 2757-65.
9. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 15: 561-73.
10. Ghany MG, Strader DB, Thomas D, Seeff L. Diagnosis, management and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-64.
11. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
12. Jowett SL, Agarwal K, Smith BC, et al. Managing chronic hepatitis C acquired through intravenous drug use. Q J Med 2001; 94: 153-8.
13. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prespective controlled study of interferon based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40: 120-4.
14. John-Baptiste A, Varenhut M, Lingley M, et al. Treatment of hepatitis C infection for current or former substance abusers in a community setting. J Viral Hepat 2009; 16: 557-6.
15. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
16. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
17. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.
18. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34: 188-93.
19. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67: 117-23.
20. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002; 36: S210-9.
21. Van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J of Gastroenterol 2003; 98: 2281-8.
22. Grebely J, Raffa JD, Meagher C, et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol 2007; 22: 1519-25.
23. Bruggman P, Falcato L, Helbling B, et al. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response in adherent patients. J Viral Hepat 2008; 15: 747-52.
24. Alvarez-Uria G, Day JN, Nasir AJ, Russell SK, Vilar FJ. Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection. Liver Int 2009; 29: 1051-5.